Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Biogen (BIIB) Stock Price & Analysis
4,336 Followers
BIIB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$189.44 - $319.76
Previous Close$216.13
Volume392.00K
Average Volume (3M)1.31M
Market Cap
$31.20B
Enterprise Value$38.81B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$7.34B
Price to Earnings (P/E)27.0
Beta0.44
Next Earnings
Jul 23, 2024EPS Estimate
$3.98Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)8.01
Shares Outstanding145,596,895
10 Day Avg. Volume1,705,415
30 Day Avg. Volume1,308,433
Standard Deviation0.10
R-Squared0.00006
Alpha0.00294
Financial Highlights & Ratios
Price to Book (P/B)144.46
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)627.50
P/FCF Ratio920.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.55
Enterprise Value/Gross Profit5.31
Enterprise Value/Ebitda20.19
Forecast
1Y Price Target
$284.96Price Target Upside32.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Biogen News
PremiumMarket News
QQQ ETF Update, 4/24/2024
PremiumMarket News
QQQ ETF Update, 4/23/2024 
PremiumMarket News
QQQ ETF Update, 4/17/2024 
PremiumMarket News
QQQ ETF Update, 4/15/2024 
PremiumMarket News
SPY ETF Update, 4/12/2024 
PremiumMarket News
QQQ ETF Update, 4/11/2024 
PremiumMarket News
SPY ETF Update, 4/10/2024 PremiumMarket News
QQQ ETF Update, 4/9/2024 Bulls Say, Bears Say
Bulls Say
Operational EfficiencyControlled expense management led to earnings per share beating estimates.
Product PerformanceLeqembi's sales slightly exceeded expectations, showing promise for its market adoption and potential future growth.
Strategic GrowthManagement's commitment to significant cost-savings and capacity for further business development could drive sustained growth and enhance the company's pipeline.
Bears Say
Drug Approval DelaysThe FDA has delayed their decision for donanemab for a third time and called for an advisory committee.
Financial PerformanceWith total revenue coming in below consensus and an increase in SG&A costs, the financial outlook appears pressured.
Product Sales ConcernsSkyclarys growth is slowing and Leqembi is not seeing major inflection yet, impacting Biogen's revenue expectations.
---
Ownership Overview
1.95% Insiders
35.95% Mutual Funds
29.14% Other Institutional Investors
32.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $189.44 and its highest was $319.76 in the past 12 months.
What is Biogen’s market cap?
Currently, no data Available
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Jul 23, 2024 which is in 81 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Apr 24, 2024. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.47 by $0.2.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.23 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is $3.98.
How many shares outstanding does Biogen have?
Biogen has 145,596,900 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $3.67 in its last earnings report, beating expectations of $3.47. Following the earnings report the stock price went up 4.561%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 4B.
---
Biogen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$284.96 (32.97% Upside)
$284.96 (32.97% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 327.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $43.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.52%
12-Months-Change
Fundamentals
Return on Equity
8.04%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
BIIB Company Deck
---
BIIB Earnings Call
Q1 2024
0:00 / 0:00
---
BIIB Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
BIIB Stock 12 Months Forecast
Average Price Target
$284.96
▲(32.97% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
8/21 ratings generated profit
1 Year Average Return
+0.97%
reiterated a buy rating 9 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of +0.97% per trade.
---